Effects of pravastatin in prevention of diabetes and mechanism thereof: Experiment with non-obese diabetic mice

National Medical Journal of China

Volumn 88, Issue 8, 2008, Pages 568-572

  Zhang, Song ^a   Yan, Xiang ^a   Zhou, Peng Cheng ^a   Huang, Gan ^a   Yang, Lin ^a   Li, Xia ^a   Lin, Jian ^a   Zhou, Zhi Guang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Autoimmunity; Diabetes; Insulitis; Pravastatin

Indexed keywords

GAMMA INTERFERON; GLUCOSE; INTERLEUKIN 14; MESSENGER RNA; PRAVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GLUCOSE URINE LEVEL; HUMAN; IMMUNE RESPONSE; INCIDENCE; INSULITIS; LOW DRUG DOSE; MICROSCOPY; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SPLEEN CELL; SUPERNATANT; TH2 CELL;

ANIMALS; CD4 LYMPHOCYTE COUNT; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERFERON-GAMMA; INTERLEUKIN-4; ISLETS OF LANGERHANS; MICE; MICE, INBRED NOD; PRAVASTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TH1 CELLS; TH2 CELLS;

EID: 43649095009     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Gillespie KM. Type 1 diabetes: pathogenesis and prevention CMAJ,2006,175:165-170.
2. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol,2005,23:447-485.
3. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol,2006,6:358-370.
4. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet,2004,363: 1607-1608.
5. Chinese source.
6. Aktas O, Waiczies S, Smorodchenko A, et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med,2003,197:725-733.
7. Brumeanu TD, Goldstein R, Casares S. Down-regulation of autoreactive T-cells by HMG-CoA reductase inhibitors. Clin Immunol,2006,119:1-12.
8. Palomer X, Calpe-Berdiel L, Verdaguer J, et al. Atorvastatin does not decrease or delay diabetes onset in two different mouse models of type 1 diabetes. Diabetologia,2005,48:1671-1673.
9. Lozanoska-Ochser B, Barone F, Pitzalis C, et al. Atorvastatin fails to prevent the development of autoimmune diabetes despite inhibition of pathogenic beta-cell-specific CD8 T-cells. Diabetes, 2006,55:1004-1010.
10. Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol,2003, 170:1524-1530.
11. Kaufman DL, Clare-Salzler M, Tian J, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature,1993,366:69-72.
12. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science,1995,268:1185-1188.
13. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature,2002, 420:78-84.
14. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev,1994,15:516-542.
15. Kukreja A, Cost A, Marker J, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest,2002,109:131-140.
16. Lindley S, Dayan CM, Bishop A, et al. Defective suppressor function in CD4 + CD25 + T-cells from patients with type 1 diabetes. Diabetes,2005,54:92-99.